Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Emapalumab Prévention des toxicités associées aux cellules CAR-T

1 octobre 2026 mis à jour par: Marcela V. Maus, M.D.,Ph.D.

Un essai de phase 2 sur l'Emapalumab pour la prévention des toxicités associées aux cellules CAR-T

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL).

The research study involves the following study interventions:

  • Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy)
  • Axicabtagene Ciloleucel or Lisocabtagene Maraleucel
  • Emapalumab

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

This is a phase 2 multi-center, open label study that is evaluating the safety and efficacy of emapalumab in preventing toxicities associated with FDA Approved, CD19-directed CAR-T in subjects with second- or third-line large B-cell non-Hodgkin's lymphoma.

A phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.

The U.S. Food and Drug Administration (FDA) has not approved emapalumab for the participants specific disease, but it has been approved for other uses.

The U.S. FDA has approved axicabtagene ciloleucel and lisocabtagene maraleucel for the participants specific disease.

This research study procedures include screening for eligibility, study treatment including collection of T cells (leukapheresis), lymphodepleting chemotherapy, treatment with emapalumab and axicabtagene ciloleucel or lisocabtagene maraleucel, and follow-up evaluations.

Once study treatment is completed, the participants will be followed for up to 24 months.

It is expected that about 28 people will take part in this research study.

Type d'étude

Interventionnel

Inscription (Estimé)

28

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02114
        • Recrutement
        • Massachusetts General Hospital
        • Chercheur principal:
          • Matthew Frigault, MD
        • Contact:
      • Boston, Massachusetts, États-Unis, 02215
        • Pas encore de recrutement
        • Dana-Farber Cancer Institute
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Or adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

  • At least 1 measurable lesion per Lugano at time of screening.

  • Age 18 or older

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

  • Adequate renal, hepatic, pulmonary and cardiac function defined as:

    • ANC ≥1000/uL
    • Platelet count ≥50,000/uL
    • Absolute lymphocyte count ≥100/uL
    • Creatinine clearance (as estimated by Cockcroft Gault or CKD-EPI) ≥ 30 mL/min
    • Serum ALT/AST ≤2.5 per institutional ULN
    • Total bilirubin ≤1.5 mg/dl, except in subjects with Gilbert's syndrome.
    • Cardiac ejection fraction ≥ 40%, no clinically significant pericardial effusion, and no clinically significant ECG findings
    • Baseline oxygen saturation >92% on room air.
  • Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential).

  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3 years.

  • Autologous stem cell transplant within 6 weeks of planned CAR-T infusion.

  • History of allogeneic stem cell transplantation.

  • Presence of uncontrolled fungal, bacterial, viral, or other infection at time of screening.

  • Known history of acute or chronic active hepatitis B or C infection. Subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America (IDSA) guidelines.

    • Patients should also be negative for latent Tb, CMV (NAT), EBV (NAT) and adenovirus (NAT) by PCR testing.
  • No evidence of active CNS disease regardless of prior CNS history.

  • History or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage within 6 months of enrollment.

  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.

  • History of symptomatic pulmonary embolism within 3 months of enrollment; ongoing anticoagulation is allowed if beyond 3 months.

  • Any medical condition likely to interfere with assessment of safety or efficacy of study treatment.

  • History of allergic reactions or severe immediate hypersensitivity reaction to any of the agents used in this study or compounds of similar chemical or biologic composition.

  • Females who are pregnant or breastfeeding or female or male participants who are not willing to practice birth control from the time of consent through 6 months after the completion of CAR-T

  • In the investigators judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.

  • History of autoimmune disease requiring ongoing systemic immunosuppression. Steroids are allowed up to 5mg predinosine-equivalent for adrenal insufficiency.

  • Receipt of a BCG vaccine within 12 weeks prior to Screening.

  • Receipt of a live or attenuated live (other than BCG) vaccine within 4 weeks prior to screeing.

  • Participants who are receiving any other investigational agents for this condition.

  • Patients anticipated to require canakinumab, JAK inhibitors, TNF inhibitors, and tocilizumab for non-CAR-T management of baseline autoimmune/inflammatory disease at the time of emapalumab initiation.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Cohort 1a

Leukapheresis will happen within approximately 5 days of eligibility confirmation.

Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.

Patients will receive emapalumab 3mg/kg on day -1.

FDA Approved CAR-T will be given once on Day 0 by intravenous infusion over about 30 minutes.

An interferon gamma (IFNγ) blocking antibody

Autres noms:
  • Gamifant
  • Anticorps monoclonal anti-interféron gamma humain (IFNγ)

Alkylating agent

Purine antagonist antimetabolite

Autologous treatment

Expérimental: Cohort 1b

Leukapheresis will happen within approximately 5 days of eligibility confirmation.

Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.

FDA Approved CAR-T will be given once on Day 0 by intravenous infusion over about 30 minutes.

Patients will start dexamethasone 10mg PO daily starting on day 0 through day +2.

Patients will receive emapalumab 3mg/kg on day +1.

An interferon gamma (IFNγ) blocking antibody

Autres noms:
  • Gamifant
  • Anticorps monoclonal anti-interféron gamma humain (IFNγ)

Alkylating agent

Purine antagonist antimetabolite

Autologous treatment

Corticosteroid

Expérimental: Cohort 2a

Leukapheresis will happen within approximately 5 days of eligibility confirmation.

Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.

Patients will receive emapalumab 3mg/kg on day -1.

Lisocabtagene maraleucel will be given once on Day 0 by intravenous infusion over about 30 minutes.

An interferon gamma (IFNγ) blocking antibody

Autres noms:
  • Gamifant
  • Anticorps monoclonal anti-interféron gamma humain (IFNγ)

Alkylating agent

Purine antagonist antimetabolite

Autologous treatment

Expérimental: Cohort 2b

Leukapheresis will happen within approximately 5 days of eligibility confirmation.

Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.

Lisocabtagene maraleucel will be given once on Day 0 by intravenous infusion over about 30 minutes.

Patients will start dexamethasone 10mg PO daily starting on day 0 through day +2.

Patients will receive emapalumab 3mg/kg on day +1.

An interferon gamma (IFNγ) blocking antibody

Autres noms:
  • Gamifant
  • Anticorps monoclonal anti-interféron gamma humain (IFNγ)

Alkylating agent

Purine antagonist antimetabolite

Corticosteroid

Autologous treatment

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Incidence of grade 2+ CRS per ASTCT
Délai: Day -1 to 24 months post treatment

Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). All participants will be monitored and assessed for grade 2+ cytokine release syndrome (CRS) for 24 months after post treatment.

Day -1 to 24 months post treatment

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Rate and severity of ICANS as per ASTCT
Délai: 30 days

Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). The rate and severity of immune cell associated neurotoxicity syndrome (ICANS) within the first 30 days of infusion.

30 days
Objective response rate (ORR)
Délai: Day -1 to 24 months post treatment

The incidence of either a complete response or a partial response by Lugano. All subjects that do not meet the criteria for an objective response by the analysis data cutoff date will be considered non-responders.

Day -1 to 24 months post treatment

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Duration of response (DOR)
Délai: From First Objective Response until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment

Among subject who experience an objective response the date of their first objective response to disease progression per Lugano or death regardless of cause. Subjects not meeting the criteria for progression or death by the analysis data cutoff date will be censored at their last evaluable disease assessment date and their response will be noted as ongoing.

From First Objective Response until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
Progression-free Survival (PFS)
Délai: From Day 0 until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment

The time from the CAR-T infusion date to the date of disease progression per Lugano or death from any cause. Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date.

From Day 0 until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
Overall survival (OS)
Délai: From Day 0 until documented date of death from any cause, assessed up to 24 months post treatment

The time from CAR-T infusion to the date of death. Subjects who have not died by the analysis data cutoff date will be censored at their last contact date.

From Day 0 until documented date of death from any cause, assessed up to 24 months post treatment

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Chercheur principal: Matthew Frigault, MD, Massachusetts General Hospital

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

18 septembre 2024

Achèvement primaire (Estimé)

1 août 2027

Achèvement de l'étude (Estimé)

1 août 2028

Dates d'inscription aux études

Première soumission

5 août 2024

Première soumission répondant aux critères de contrôle qualité

8 août 2024

Première publication (Réel)

12 août 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

1 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Délai de partage IPD

Data can be shared no earlier than 1 year following the date of publication

Critères d'accès au partage IPD

Contact the Partners Innovations team at http://www.partners.org/innovation

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .